Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

FORTIS-M: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Oral Talactoferrin in Addition to Best Supportive Care in Patients With Non-small Cell Lung Cancer Who Have Failed Two or More Prior Treatment Regimens

NCT00707304 is registered in ClinicalTrials.gov with Agennix as lead sponsor.

NCT NCT00707304
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00707304 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
FORTIS-M: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Oral Talactoferrin in Addition to Best Supportive Care in Patients With Non-small Cell Lung Cancer Who Have Failed Two or More Prior Treatment Regimens
Lead sponsor
Agennix
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2008
Completion date
August 31, 2012
Enrollment
742 (actual)
Sites
189

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer